Hualan Biological Engineering Inc.

SZSE:002007 Stock Report

Market Cap: CN¥30.5b

Hualan Biological Engineering Future Growth

Future criteria checks 2/6

Hualan Biological Engineering is forecast to grow earnings and revenue by 18.7% and 18% per annum respectively. EPS is expected to grow by 19.7% per annum. Return on equity is forecast to be 12.5% in 3 years.

Key information

18.7%

Earnings growth rate

19.7%

EPS growth rate

Biotechs earnings growth43.4%
Revenue growth rate18.0%
Future return on equity12.5%
Analyst coverage

Good

Last updated08 Nov 2024

Recent future growth updates

Recent updates

Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Nov 18
Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate

Oct 07
Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate

Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Aug 22
Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 26
Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Jun 09
Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Jun 07
These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

May 21
Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Feb 27
Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Earnings and Revenue Growth Forecasts

SZSE:002007 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20267,2901,9862,3241,82610
12/31/20256,2621,7162,4761,64212
12/31/20245,1361,3621,6272,1307
9/30/20244,9201,3384361,113N/A
6/30/20245,4091,395256900N/A
3/31/20245,2491,3923461,027N/A
12/31/20235,3421,4825921,346N/A
9/30/20234,8281,2438071,538N/A
6/30/20233,7531,0201,0991,713N/A
3/31/20234,7571,1948351,268N/A
1/1/20234,5171,076563957N/A
9/30/20224,6771,139136662N/A
6/30/20225,4971,42554704N/A
3/31/20224,4531,2774741,225N/A
1/1/20224,4361,2996211,432N/A
9/30/20215,3111,7091,0161,642N/A
6/30/20214,9251,5599071,594N/A
3/31/20214,9691,6217641,495N/A
12/31/20205,0231,6137041,325N/A
9/30/20204,1341,2846081,166N/A
6/30/20203,6841,2889021,295N/A
3/31/20203,6821,2719531,271N/A
12/31/20193,7001,2831,0901,363N/A
9/30/20193,8191,3441,0881,334N/A
6/30/20193,4181,1941,2141,451N/A
3/31/20193,3511,1921,2551,440N/A
12/31/20183,2171,1401,1091,293N/A
9/30/20182,738961746864N/A
6/30/20182,556843N/A590N/A
3/31/20182,392773N/A308N/A
12/31/20172,368821N/A177N/A
9/30/20172,195792N/A146N/A
6/30/20172,091801N/A120N/A
3/31/20172,061843N/A203N/A
12/31/20161,935780N/A330N/A
9/30/20161,767737N/A443N/A
6/30/20161,671690N/A585N/A
3/31/20161,585632N/A549N/A
12/31/20151,472589N/A549N/A
9/30/20151,386575N/A501N/A
6/30/20151,372563N/A429N/A
3/31/20151,263514N/A429N/A
12/31/20141,243538N/A497N/A
9/30/20141,237547N/A541N/A
6/30/20141,141530N/A501N/A
3/31/20141,104519N/A503N/A
12/31/20131,118475N/A511N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002007's forecast earnings growth (18.7% per year) is above the savings rate (2.8%).

Earnings vs Market: 002007's earnings (18.7% per year) are forecast to grow slower than the CN market (26.2% per year).

High Growth Earnings: 002007's earnings are forecast to grow, but not significantly.

Revenue vs Market: 002007's revenue (18% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 002007's revenue (18% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 002007's Return on Equity is forecast to be low in 3 years time (12.5%).


Discover growth companies